再酯化甘油三酯型ω-3脂肪酸治疗伴睑板腺功能障碍的干眼病:一项随机临床试验
这项双盲、平行组随机临床试验在7家机构纳入132例伴睑板腺功能障碍的干眼病患者,比较每日再酯化甘油三酯型ω-3脂肪酸(二十碳五烯酸1680 mg与二十二碳六烯酸560 mg)与葡萄籽油3000 mg。从基线至6周和12周,两组的眼表疾病指数(OSDI)变化差异均未达统计学显著;安全性参数及与补充剂相关的不良事件在两组均无变化。
要点
- ω-3组与葡萄籽油组从基线至6周的OSDI变化差异为-5.4(95%CI -12.15至1.33;P=0.12),未达统计学显著。
- 从基线至12周的OSDI变化差异为-3.9(95%CI -10.90至3.13;P=0.28),未达统计学显著。
- 两组安全性参数及与补充剂相关的不良事件均无变化。
核心结论
- 这项随机临床试验未显示再酯化甘油三酯型ω-3对改善伴睑板腺功能障碍的干眼病症状有益,尽管每组评估的受试者不足60例。
- 作者认为,本研究的任何次要结局都应被视为未来评估再酯化甘油三酯型ω-3对伴睑板腺功能障碍干眼病作用的假设来源。
研究设计与样本
- 这是一项双盲、平行组随机临床试验,于2020年9月至2023年1月在7家机构开展。
- 共纳入132例伴睑板腺功能障碍的干眼病患者,平均(SD)年龄50.6(13.8)岁,女性103例(78.0%)。
- 患者被随机分配到ω-3组(每日接受二十碳五烯酸1680 mg和二十二碳六烯酸560 mg)或葡萄籽油组(每日接受葡萄籽油3000 mg)。
主要发现
- ω-3组与葡萄籽油组的平均(SD)基线OSDI评分分别为43.5(16.5)和44.1(16.6)。
- ω-3组有58例(87.9%)、葡萄籽油组有57例(86.4%)完成了12周随访。
- 两组对膳食补充剂摄入的依从性无差异(ω-3组95.8%,葡萄籽油组95.4%)。
- ω-3组从基线至6周和12周的OSDI(SD)变化分别为-20.5(16.0)和-22.7(15.7),葡萄籽油对照组分别为-15.1(20.2)和-18.8(21.7)。
- 6周时组间差异为-5.4(95%CI -12.15至1.33;P=0.12),12周时为-3.9(95%CI -10.90至3.13;P=0.28)。
局限性
- 每组评估的受试者不足60例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Taking ω-3 supplements has been associated with a reduction in symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD). However, a recent relatively large clinical trial concluded that treating DED with ω-3 consumption was ineffective, potentially warranting additional investigations. OBJECTIVES: To investigate the effect of re-esterified triglyceride (rTG) ω-3 fatty acid supplementation on DED associated with MGD. DESIGN, SETTING, AND PARTICIPANTS: This double-masked, parallel-group, randomized clinical trial was conducted at 7 institutions from September 2020 to January 2023. Patients with DED associated with MGD were included and randomly assigned to the ω-3 group (received 1680 mg of eicosapentaenoic acid and 560 mg of docosahexaenoic acid), whereas those in the grape-seed group received 3000 mg of grape-seed oil daily. INTERVENTIONS: rTG ω-3 Fatty acid supplementation vs grape-seed oil. MAIN OUTCOME MEASURES: The primary end point was the Ocular Surface Disease Index (OSDI) from baseline to 6 and 12 weeks. The safety parameters were visual acuity and intraocular pressure change. RESULTS: A total of 132 patients (mean [SD] age, 50.6 [13.8] years; 103 female [78.0%]) were included in this study. The mean (SD) baseline OSDI scores of the ω-3 and grape-seed groups were 43.5 (16.5) and 44.1 (16.6), respectively. A total of 58 patients (87.9%) and 57 patients (86.4%) in the ω-3 and grape-seed groups, respectively, completed 12 weeks of follow-up. There were no differences in compliance with the dietary supplement intake between groups (ω-3, 95.8% and grape-seed, 95.4%). The OSDI (SD) change from baseline to 6 and 12 weeks was -20.5 (16.0) and -22.7 (15.7), respectively, in the ω-3 group and -15.1 (20.2) and -18.8 (21.7), respectively, in the grape-seed control group (difference at 6 weeks = -5.4; 95% CI, -12.15 to 1.33; P = .12 and at 12 weeks = -3.9; 95% CI, -10.90 to 3.13; P = .28). There were no changes in safety parameters or adverse events related to taking the dietary supplement in either group. CONCLUSIONS AND RELEVANCE: This randomized clinical trial did not show a benefit of the rTG form of ω-3 for ameliorating symptoms of DED associated with MGD, although fewer than 60 participants were evaluated in each group. Any secondary outcomes from this study should be considered for hypothesis generation of future evaluations of the effect of the rTG form of ω-3 on DED associated with MGD. TRIAL REGISTRATION: CRIS Identifier: KCT0004927.
引用
- Eom Y, Jun I, Jeon HS, et al. Re-Esterified Triglyceride ω-3 Fatty Acids in Dry Eye Disease With Meibomian Gland Dysfunction: A Randomized Clinical Trial. JAMA Ophthalmol. 2024. PMID: 38753336. doi:10.1001/jamaophthalmol.2024.1482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。